Because of World Immunisation Week 2016, our partner DSW interviewed TBVI’s Director of Resource Mobilisation René Coppens.
WIW 2016 – TBVI: “TB research severely underfunded”
DSW: Our coverage of World Immunisation Week continues, with an interview with Rene Coppens of TBVI, a Europe-based organisation working to advance the development of the next generation of TB vaccines.
DSW: Can you tell our readers a little about TBVI? What is the organisation’s goal?
Rene Coppens: The TuBerculosis Vaccine Initiative (TBVI) is a non-profit foundation that facilitates the discovery and development of new, safe and effective TB vaccines that are accessible and affordable for all people.
What kind of approach does TBVI take to vaccine development, and to the broader global health R&D field?
As a Product Development Partnership (PDP), TBVI integrates, translates and prioritises R&D efforts to discover and develop new TB vaccines and biomarkers for global use. TBVI has evolved into an unique non-profit Product Development Partnership (PDP) that consists of two parts: